Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNβ in multiple sclerosis patients
- 31 July 2008
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 336 (2) , 113-118
- https://doi.org/10.1016/j.jim.2008.03.014
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based studyMultiple Sclerosis Journal, 2007
- Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-betaMultiple Sclerosis Journal, 2007
- Measured Neutralizing Titers of IFN-β Neutralizing Antibodies (NAbs) Can Depend on the Preparations of IFN-β Used in the AssayJournal of Interferon & Cytokine Research, 2007
- Development of Luciferase Reporter-Based Cell AssaysASSAY and Drug Development Technologies, 2006
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- Neutralising antibodies to interferon beta during the treatment of multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2002
- The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction UnitJournal of Interferon & Cytokine Research, 2001
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998
- A Novel Sensitive and Selective Bioassay for Human Type I InterferonsJournal of Interferon & Cytokine Research, 1998
- Domains of Interaction between Alpha Interferon and its Receptor ComponentsJournal of Molecular Biology, 1994